D
endritic cells (DCs) play an important role in immune tolerance (1) . Mice lacking DCs spontaneously develop fatal autoimmunity (2) , supporting the significant contribution of DCs to the development or maintenance of tolerance. The tolerogenic role of DCs is dependent on steady state selfantigen presentation. At rest, DCs continuously endocytose and present self-antigens (3) (4) (5) . This presentation results in the unresponsiveness or deletion of self-reactive T cells (3, 6) . It also mediates the development of regulatory T cells, a unique T cell subset equipped with potent immune-suppressive functions (7, 8) .
Targeting Ags to resting DCs using a DC-specific Ab has been suggested as a potential therapeutic strategy for the induction of tolerance against auto-antigens (9, 10). Injection of nonobese diabetic (NOD) mice with a b-cell Ag-fused DEC-205 mAb has been shown to prevent diabetes (11, 12) . Injection with myelin oligodendrocyte glycoprotein Ag fused with DEC205 or Langerin mAbs has been shown to suppress experimental autoimmune encephalomyelitis in mice (13, 14) . However, it is not known whether these Abs would target DCs in humans as efficiently as in mice, because the protein expression pattern differs significantly between species. Indeed, human DEC-205 is expressed on more leukocyte populations than mouse DEC-205, including B cells, T cells, monocytes, macrophages, and NK cells (15) . In addition, it is hard to predict the adverse effects elicited by Ab binding.
Because Abs are bivalent, their binding to cells can cross-link cell surface molecules. Surface molecule cross-linking often triggers stimulatory signaling in cells, the outcome of which varies depending on cell type (16) (17) (18) (19) . Importantly, clinical development of human Abs is challenging, and it requires laborious manufacturing procedures, including the initial generation of mAbs in vivo, followed by extensive modifications of the Abs in vitro (20) . Thus, there is a need for an alternative method to target DCs and for an animal model to better gauge its targeting efficacy in humans.
Targeting the high-affinity IgE receptor FcεRI with Ag-conjugated IgE could be a promising alternative method. Whereas FcεRI is expressed only by mast cells and basophils in steady state mice, it is additionally expressed by DCs and monocytes in humans (21) . The FcεRIa-chain, a member of the Ig superfamily, binds IgE Fc domain at a 1:1 ratio of receptor to IgE with unusually high affinity (K d = ∼10 210 M) (22) . When IgE/FcεRI complexes are cross-linked by multivalent Ags, a strong inflammatory signal is transmitted to cells, resulting in degranulation of mast cells and basophils and Ag presentation and cytokine production in DCs and monocytes (21) . When bound by IgE alone, however, FcεRI does not transmit signaling in general; however, certain IgE clones, namely cytokinergic IgE, appear to induce signaling through IgE Fv domain (23) .
In this study, we examined whether the human IgE Fc domain could be used to induce Ag-specific tolerance in vivo by using the previously described hFcεRIa-transgenic (Tg) mice (24) , which express human FcεRIa under the control of its own promoter. We demonstrate that Ag-Fcε fusion proteins strongly bind both human DCs and hFcεRIa-Tg mouse DCs, that such Ags are presented to Ag-specific T cells with a 1000-2500 fold greater efficiency than unlinked Ag are, and that this presentation leads to Ag-specific T cell deletion and tolerance.
Materials and Methods
Mice and cell lines hFcεRIa transgenic mice (24) , SMARTA mice (25), Foxp3 GFP mice (26) , and U937 cells transfected with hFcεRI (27) have been described previously. The human IgE secreting myeloma cell line U266 was purchased from American Type Culture Collection. B6.SJL-Ptprc a Pepc b /BoyJ, OT-II, and OT-I mice were purchased from Jackson Laboratory. All mice were housed in the University of California San Francisco (UCSF) animal facility, and all experiments and procedures were performed according to protocols approved by the UCSF Institutional Animal Ethics Committee.
Human blood
Healthy human blood was obtained through an ongoing study under the UCSF Institutional Review Board-approved protocol 10-02596 with informed written consent.
Abs
Abs to human CD3 (HIT3a), CD19 (HIB19), CD56 (MEM188), CD14 (HCD14), HLA-DR (L243), BDCA1 (L161), CD123 (6H6), hFcεRIa (CRA-1), IgE (MHE-18), murine CD49b (Dx5), CD11b (M1/70), GR1 (RB6-8C5), Thy1.1 (HIS51), TCRVa2 (B20.1), TCRVb5 (MR9-4), CD45.1 (A20), CD11c (N418), MHCII (TIB120), and isotype control Ab to hFcεRIa Ab (mouse IgG2b k , eBMG2b) were purchased from BioLegend or eBioscience. Anti-CD131 (JORO50) was purchased from BD Biosciences. Anti-BDCA-3 (M80) and mPDCA1 (JF05-1C2.4.1) were purchased from Miltenyi Biotec. Anti-His (Penta) was purchased from Qiagen. HRP-conjugated Abs were purchased from Biosource
Flow cytometry
Human PBMCs were isolated from whole blood via density gradient centrifugation using Ficoll Plaque Plus (GE Healthcare) (28) . Murine blood was collected via cardiac puncture and PBMCs were isolated. Cells were labeled with various cell surface Abs and acquired on a FACS LSRII system (BD Biosciences 
Construction of Ag-Fc«
hIgE cDNA was cloned from the IgE-secreting myeloma cell line U266 (ATCC) using RT-PCR. The Cε2-Cε4 cDNA was amplified using the following primer pair: 59-GGAATTCTGCTCCAGGGACTTCACC-39 and 59-CGATATCTCAGTGGTGATGGTGATGATGAGAACCACCAGAT-TTACCGGGATTTACAGAC-39, where the reverse primer encodes for the SGGS-linker and the 6xHIS tagged C-terminal end of the Cε4 sequence. This PCR product was cloned in-frame using EcoRI/EcoRV digestion into a pcDNA3.1 expression vector (Invitrogen), which had a previously inserted IRES-EGFP downstream of the IgE sequence. A V k signal sequence (METDTLLLWVLLLWVPGSTGD) followed by SGGS-linker sequences and a ClaI cloning site were inserted at the N terminus by NheI/EcoRI digestion using the following DNA oligo molecules: 59-CTAGCTAGCATGGAGACAGACACACTCCTGCTATGGGTACTGCTG-CTCTGGGTTCCAGGTTCCACTGGTGACTCTGGTGGTTCTATCGAT-TCTGGTGGTTCTGAATTCC-39 and 59-GGAATTCAGAACCACCAGA-ATCGATAGAACCACCAGAGTCACCAGTGGAACCTGGAACCCAGA-GCAGCAGTACCCATAGCAGGAGTGTGTCTGTCTCCATGCTAGCTA-G-39. The cDNAs for OVA peptide (ISQAVHAAHAEINEAGR, 323-339) and OVA peptide (SIINFEKL, 257-264) were cloned from pCI-neo-cOVA plasmid (Addgene) using RT-PCR. The primer pair for OVA peptide (323-339) was: 59-CCATCGATTCTGGTGGTTCTGCAGAGAGCCTGAAGA-TA-39 and 59-GGAATTCAGAACCACCAGATGACCCTACCACCTCTC-T-39 and the primer pair for OVA peptide (257-264) was: 59-CCATCGAT-TCTGGTGGTTCTGATGAAGTCTCAGGCCTTGAGCA-39 and 59-GG-AATTCAGAACCACCAGATTCCATAACATTAGAACTGG-39. Both PCR products were cloned in-frame using ClaI/EcoRI digestion. 293T cells grown in protein-free media were transfected using FuGene HD transfection reagent (Roche). The transfection efficiency was ∼60-70%, based on the percentage of EGFP + cells. Supernatants were collected, and the secreted fusion proteins were purified over Ni-NTA resin columns (Thermo Scientific) and eluted from the resin by increasing concentrations of imidazole (Acros organics) in buffer solutions. Eluted proteins were extensively dialyzed against PBS and quantitated by 10% SDS-PAGE followed by Coomassie blue staining, where BSA was used as a standard protein.
In vitro Ag presentation assay . Blood leukocytes and splenocytes were isolated from hFcεRIa-Tg mice and stained using cell-identification Abs (anti-CD11c, MHCII, Dx5, CD131, CD11b, GR1, and mPDCA1) and hFcεRIa or isotype control Ab. Cells were gated as described in Materials and Methods. Anti-FcεRIa Ab staining is shown black, and isotype control Ab staining is shown gray. Data are representative of five independent experiments. incubated with 10 mg/ml anti-CD3 and 20 mg/ml anti-CD28 Abs (BD Biosciences).
In vivo Ag presentation assay
Indicated mice were injected i.v. with 0.5-1 3 10 6 CTV or CFSE-labeled Ag-specific CD4 + or CD8 + T cells. One day later, mice were injected i.v. with the indicated amounts of fusion proteins, OVA peptide (323-339; China peptides), or OVA protein (Fisher Scientific). Three, seven, or twelve days later, a single-cell suspension was prepared from spleen, lymph nodes, or blood, and stained for flow cytometry using fluorophore-labeled Abs directed against CD4, CD8, TCRVa2, and CD45.1.
In vivo Treg induction assay
Mice were injected i.v. with 0.5-1 3 10 6 CTV-labeled CD4 + GFP 2 T cells sorted from Foxp3
GFP OT-II mice expressing the congenic marker Thy1.1. One day later, mice were injected i.v. with OVAp-Fcε. Three, seven, or twelve days later, CD4 + T cells were isolated from whole spleen by using anti-CD4 Ab magnetic beads (Stemcell Technologies), stained using fluorophore-labeled Abs directed against CD4, CD8, TCRVb5, and Thy1.1, and analyzed by flow cytometry. GFP + CD4 + Thy1.1 + TCRVb5 + cells were gated and cell numbers were determined.
T cell restimulation assay and delayed-type hypersensitivity assay IFA alone. Twenty-four hours later, thickness of each footpad was measured using a caliper rule.
Results

Fc«RI is expressed on BDCA1
+ DCs, PDCs, monocytes, and basophils in human PBMCs
To determine which cells express FcεRI in human blood, we performed flow cytometry on human PBMCs using an anti-FcεRI Ab and a panel of cell type-specific Abs. We found that FcεRI was expressed on a small fraction of PBMCs and that this fraction was composed of more than one cell population, as indicated by heterogeneous labeling by FcεRI and CD14 Abs (Fig. 1A, upper  panel) . Further analysis revealed that these FcεRI-expressing cells consisted of basophils, plasmacytoid DCs (PDCs), BDCA1 + DCs, and monocytes (Fig. 1A , lower panel). To confirm that these cell types indeed expressed FcεRI, we gated them independently of FcεRI expression using cell type-specific markers (Supplemental Fig. 1 ) and subsequently examined FcεRI expression. We found that BDCA1 + DCs, PDCs, and basophils all expressed FcεRI homogeneously, whereas monocytes appeared to express it heterogeneously ( Fig. 1B) . We also examined BDCA3 + DCs, T cells, B cells, and NK cells by gating them using specific markers (Supplemental Fig. 1 ). None of these cells expressed FcεRI at appreciable levels (Fig. 1B) . Thus, FcεRI is specifically expressed in BDCA1 + DCs, PDCs, basophils, and a subpopulation of monocytes in human PBMCs.
hFc«RIa-Tg mice have a similar pattern of hFc«RI expression compared with humans
To determine whether hFcεRIa-Tg mice express hFcεRI in a similar fashion to humans, we performed flow cytometry of blood cells from hFcεRIa-Tg mice using the same anti-human FcεRIa Ab. We found that basophils, monocytes, and PDCs expressed hFcεRI; cDCs also expressed it, although levels were significantly lower than for other cell types ( Fig. 2A) . No FcεRI was found on lymphocytes, including B cells (Fig. 2A) . A similar expression profile of hFcεRI was found in the spleen (Fig. 2B) . Thus, hFcεRIa-Tg mice express hFcεRI in cell types similar to humans, albeit with slightly different expression levels.
Generation of OVAp-Fc« recombinant protein
Having determined that hFcεRIa-Tg mice express hFcεRI similarly to humans, we decided to use these mice to examine whether IgE could be exploited to target Ags to DCs for presentation in vivo. For this study, we generated an OVAp-Fcε fusion protein. First, a cDNA was cloned encoding a V k signal sequence linked sequentially to OVA peptide (323-339; OVAp), human IgE Cε2-Cε4 domains (Fcε), and 6XHis tag (Fig. 3A) . In this study, the signal peptide was included to let the recombinant protein be secreted into the cell culture media. OVA peptide (323-339) was included as a model Ag, the presentation of which can be readily determined by using OT-II transgenic mice, which express OVAspecific TCRs. The 6XHis tag was added to ease purification of recombinant protein via affinity chromatography. This cDNA construct was transfected into 293T cell lines cultured in proteinfree media. Media was subsequently examined for the presence of the recombinant protein by using nonreducing SDS-PAGE followed by Western blot analysis using an anti-hIgE Ab and an anti-His Ab. A single protein band was detected at the m.w. of OVAp-Fcε dimers (Fig. 3D, 3E , "Supernatant"), which was expected because IgE heavy chains dimerize via intermolecular disulfide bonds (Fig. 3B) (29) . To confirm dimerization, we ran the same sample on a reducing SDS-PAGE. As predicted, the reduced protein band appeared at about half the m.w. of the nonreduced protein band (Fig. 3F ). We enriched and purified the recombinant protein by collecting media and running it through a Ni-NTA column. We found that the anti-IgE and antiHis reactive band was eluted from the column at high purity (Figs. 3C-3E, "Eluates").
Next, we determined whether OVAp-Fcε specifically binds to hFcεRI. OVAp-Fcε was incubated with U937 cells that were either untransfected or transfected with hFcεRI (27); flow cytometry was performed using an anti-hIgE Ab that specifically reacts with hIgE Fc domain. We found that anti-hIgE Ab stained hFcεRI-transfected U937 cells but not untransfected cells (Fig. 3G) , indicating that OVAp-Fcε specifically binds to FcεRI. We also determined whether OVAp-Fcε cross-links FcεRI. OVAp-Fcε was incubated with hFcεRIa-Tg mouse bone marrow-derived mast cells, and degranulation was quantified by hexosaminidase release assay (30) . No hexosaminidase was released upon incubation with the construct (Supplemental Fig. 2 ), indicating that OVAp-Fcε does not cross-link FcεRI.
OVAp-Fc« binds to human DCs in vitro and to DCs of hFc«RIa-Tg mice in vivo Next, we examined whether OVAp-Fcε binds to human DCs. OVAp-Fcε was incubated with human PBMCs, and its binding to cells was determined by flow cytometry with an anti-His Ab to avoid unintentional signal from endogenous IgE bound to FcεRI. We found that anti-His Ab bound to all FcεRI-expressing cells, including BDCA1 + DCs, PDCs, basophils, and monocytes, but not to FcεRI-nonexpressing cells such as BDCA3 + DCs (Fig. 4A ). This finding indicates that OVAp-Fcε specifically binds to human DCs and other FcεRI-expressing cells.
Next, we examined whether OVAp-Fcε binds to DCs of hFcεRIa-Tg mice in vivo. OVAp-Fcε was injected i.v. into hFcεRIa-Tg mice. One hour after injection, we isolated blood cells and performed flow cytometry using anti-His Ab and cell type specific Abs. We found that anti-His Ab bound to cDCs and other hFcεRI-expressing cells such as PDCs, but not to FcεRI-negative cells such as B cells (Fig. 4B, upper panel) . Like in blood, anti-His Ab stained cDCs and other hFcεRI-expressing cells, but not B cells in the spleen (Fig. 4C) . To confirm that OVAp-Fcε binding to DCs is mediated by hFcεRI, we performed the same experiment using Tg-negative control mice and found no anti-His Ab binding in any cell types (Fig. 4B, lower panel) . Thus, OVApFcε binds to DCs in hFcεRIa-Tg mice in an hFcεRI-dependent manner.
Ag targeting to hFc«RI enhances Ag presentation in hFc«RIa-Tg mice by 1000-2500 fold in vivo
To determine whether Ag targeted to FcεRI through our Ag-Fcε fusion protein is presented in vivo, we injected OVAp-Fcε into hFcεRIa-Tg mice that had been adoptively transferred with a mixture of CTV-labeled OT-II and CFSE-labeled SMARTA mouse CD4 + T cells. We included SMARTA T cells, which are specific for an irrelevant Ag, to determine whether T cell proliferation is Ag-specific or whether it is the result of nonspecific T cell activation. Proliferation of OT-II and SMARTA CD4 + T cells was examined 3 d after OVAp-Fcε injection by determining the dilution of CFSE and CTV by flow cytometry. As expected, dilution of CTV was readily detected while dilution of CFSE was not observed (Fig. 5A ). This finding indicates that Ag targeted to FcεRI through Ag-Fcε fusion protein is presented to Ag-specific T cells in hFcεRIa-Tg mice, resulting in the restricted proliferation of only Ag-specific cells.
Next, we examined the degree to which targeting Ags to FcεRI enhances Ag presentation. For this study, CTV-labeled OT-II CD4 + T cells were transferred into hFcεRIa-Tg and Tg 2 control mice. One day later, mice were injected i.v. with 0.05-0.5 mg OVAp-Fcε. Spleens were harvested 3 d later, and the dilution of CTV was examined by flow cytometry. We found that OTII CD4 + T cells proliferated in hFcεRIa-Tg mice, but not in control mice (Fig. 5B) . To determine whether the lack of OT-II T cell proliferation in control mice is due to a general defect in Ag processing or presentation of these mice, we injected hFcεRIa-Tg mice and non-Tg control mice with OVA Ags at high doses, such as 10 mg OVA peptide (323-339) or 50 mg OVA protein. We found that OT-II CD4 + T cells proliferated in control mice and hFcεRIa-Tg mice to a similar degree (Fig. 5C, 5D ), indicating that Ag processing and presentation are not significantly different between Tg + and Tg 2 mice. Thus, it is the targeting of OVA to FcεRI that dramatically enhances OTII T cell proliferation.
To quantify the increase in Ag presentation efficiency when Ags were targeted to FcεRI via IgE, we compared the degree of OT-II T cell proliferation in hFcεRIa-Tg mice injected with OVAp-Fcε versus OVA protein or peptide (323-339). We found that 0.1 mg OVAp-Fcε (which contains an equivalent molar quantity of 0.004 mg OVA peptide [323-339]) induced OTII T cell proliferation to a degree similar to 10 mg of OVA peptide (323-339; Fig. 5E ), and that 0.05 mg of OVAp-Fcε elicited an OT-II T cell proliferation equivalent to that of 50 mg OVA protein (Fig. 5F ). These findings indicate that Ag presentation increases by 1000-2500 fold when Ag is targeted to FcεRI in hFcεRIa-Tg mice.
It is noteworthy that targeting Ags to FcεRI did not appear to enhance Ag presentation to CD8 + T cells. We generated OVA (257-264)-Fcε and injected it into hFcεRIa-Tg and Tg 2 control mice that had received OT-I CD8 + T cells expressing OVA (257-264)-specific TCR. We found that OT-I CD8 + T cells proliferated in Tg + and Tg 2 mice to similar degrees (Supplemental Fig. 3 ),
indicating that DC targeting of Ags via FcεRI only enhances Ag presentation to CD4 + T cells in this mouse model.
Fc«RI-targeted Ags are specifically presented by cDCs in hFc«RIa-Tg mice
To investigate which FcεRI-expressing cells present OVA targeted to FcεRI, we i.v. injected hFcεRI Tg-mice with OVAp-Fcε. After 24 h, cDCs, PDCs, basophils, monocytes, and B cells were isolated from spleen by FACS. Each of the isolated cell types was cultured with CTV-labeled OT-II CD4 + T cells, and the dilution of CTV was determined by flow cytometry 4 d later. We found that dilution of CTV was limited to when OT-II CD4 + T cells were cultured with cDCs, although the extent of proliferation was markedly weaker that what was seen in vivo (Fig. 6A) . This weak proliferation is likely due to low number of APCs used in this assay because of the scarcity of basophils in spleens. Nevertheless, quantification of data from three independent experiments indicated that cDCs, but no other cell type, induced OT-II proliferation at significant levels (Fig. 6B) . We also performed the [ 3 H]thymidine uptake, which is perhaps more sensitive and quantitative than CTV dilution assay. As shown in Fig. 6C, [ 3 H]thymidine was incorporated into OT-II T cells incubated with cDCs, but not any (Figs. 2, 4) , cDCs are the only cells that present OVA.
Ag targeting to Fc«RI results in Ag-specific CD4
+ T cell deletion in hFc«RIa-Tg mice Next, we examined the fate of OT-II CD4 + T cells following proliferation in hFcεRIa-Tg mice injected with OVAp-Fcε. For this study, we adoptively transferred CD45.1 expressing CTVlabeled OT-II CD4 + T cells into hFcεRIa-Tg mice, injected the mice i.v. with OVAp-Fcε the following day, and determined the frequency and CTV dilution of CD45.1 + cells in the spleen at days 3, 7, and 12 after injection. We observed substantial dilution of CTV on day 3, indicating OT-II CD4 + T cell proliferation. However, proliferation did not continue; in fact, there were fewer CD45.1 + cells observed on day 7, and they completely disappeared by day 12 (Fig. 7A) . When we quantitated the frequency of CD45.1 + cells in the spleen, lymph node, and blood, we found that these cells were disappearing over time from all these organs, indicating systemic deletion (Fig. 7B) . To determine whether hFcεRIa-Tg mice have an intrinsic defect in expanding Ag-specific T cells, we examined OT-II CD4 + T cell expansion in these mice after injection of OVAp-Fcε together with the immunostimulatory agent LPS. We found that OT-II CD4 + T cells proliferated substantially and continuously for the entire 12 d of examination in spleen, LN, and blood (Fig. 7C, 7D ). This finding indicates that hFcεRIa-Tg mice are capable of expanding Ag-specific T cells when Ag is targeted to hFcεRI in the presence of inflammatory stimuli, but delete them when Ag is targeted to hFcεRI in the absence of such stimuli.
We also examined whether targeting Ags to hFcεRI induces Agspecific regulatory T cells (Tregs) in hFcεRIa-Tg mice. Mice were adoptively transferred with GFP 2 CD4 + T cells that were isolated from Foxp3 GFP OT-II mice by FACS (Fig. 8A) and labeled with CTV. OVAp-Fcε was injected i.v. the next day, and GFP expres- (Fig. 8B, 8C) . Thus, Ag-targeting to hFcεRI hardly induces Tregs.
Ag-Fc« fusion protein inhibits development of Ag-specific T cell immunity in Fc«RIa-Tg mice
Lastly, we investigated whether targeting Ags to FcεRI could inhibit development of Ag-specific T cell immunity and induce T cell tolerance in vivo. For this study, we examined whether OVAp-Fcε could prevent hFcεRIa-Tg mice from developing delayed-type hypersensitivity against OVA. hFcεRIa-Tg mice adoptively transferred with OT-II CD4 + T cells were injected i.v. with either OVAp-Fcε or PBS. Seven days later, mice were immunized with OVA peptide mixed with IFA. An additional 7 d later, OVA-specific T cell immunity was determined using either in vitro restimulation assay or DTH assay. For the in vitro restimulation assay, splenocytes were isolated from mice, incubated with OVA peptide, and examined for proliferation using [ (Fig. 9B) . To verify that this inhibitory effect was mediated by hFcεRI, the same experiment was performed using control mice that do not express hFcεRI. Splenocytes from OVAp-Fcε-injected control mice incorporated [ 3 H]thymidine as much as those from PBS-injected hFcεRIa-Tg mice did (Fig. 9B) . Thus, OVAp-Fcε inhibits development of OVA-specific T cell immunity only when hFcεRI is expressed.
For DTH assay, mice were injected into the left footpads with OVA peptide mixed with IFA, and into the right footpads with IFA alone. Twenty-four hours after injection, the thickness of each footpad was measured. The thickness of the left footpad was subtracted from that of the right footpad to determine swelling induced by OVA rechallenge (Fig. 8A) . We found that both PBS and OVAp-Fcε-injected mice showed appreciable swelling, but the degree was markedly less in OVAp-Fcε-injected mice, suggesting that OVAp-Fcε injection significantly inhibited mice from 3 H]Thymidine uptake assay. Experiments were performed twice using three mice per group in each experiment. Data show one representative experiment with mean 6 SEM. (C) DTH assay. Thickness of right footpad subtracted by that of left footpad is indicated as "swelling." Experiments were performed three times using three to four mice per group in each experiment. Data represent mean 6 SEM of measurements made from total 10 mice for each group. ***p , 0.005. developing DTH (Fig. 8C) . Importantly, OVAp-Fcε failed to inhibit Tg 2 control mice from developing DTH (Fig. 8C) indicating that the inhibitory effect of OVAp-Fcε in DTH development requires hFcεRI expression. Taken together, these findings demonstrate that Ag targeting to FcεRI inhibits the development of Ag-specific T cell immunity and induces T cell tolerance.
Discussion
In this study, we have found that Ag-Fcε fusion proteins can be exploited to target Ags to DCs and induce Ag-specific T cell tolerance. We found that Ag-Fcε bound to human DCs in vitro and to DCs of hFcεRIa-Tg mice in vivo, and that injection of hFcεRIa-Tg mice with Ag-Fcε resulted in Ag presentation by DCs and subsequent systemic deletion of Ag-specific T cells. Importantly, injection of Ag-Fcε into hFcεRIa-Tg mice significantly inhibited these mice from developing DTH. Previous studies have indicated that the efficiency of Ag presentation can be increased by 100-1000 fold when Ags are conjugated with DC-specific Abs such as anti-DEC-205, DECTIN-1, DNGR1, DCIR, Langerin, Treml4, or DC-SIGN (9, 14, (31) (32) (33) . We found in hFcεRIa-Tg mice that Ags conjugated with human Fcε were presented by DCs at 1000-2500 fold higher efficiency than unconjugated Ags were. We predict that the efficiency of targeting of this construct to human DCs will be even higher than in hFcεRIa-Tg mice, because human DCs express much higher levels of FcεRI than hFcεRIa-Tg mouse DCs do. Thus, the efficiency of Ag presentation in humans may increase markedly when Ags are conjugated with Fcε than when it is conjugated with DCspecific Ab. In addition, generation of Ag-Fcε fusion protein is more straightforward, as described in this study, and perhaps more cost-effective than the generation of Ag-DC-specific Ab fusion protein. A single cDNA cloning and transfection will generate AgFcε; there is no need to immunize animals, generate and select hybridomas, and humanize selected Abs.
The mechanism by which Fcε-linked Ag is presented to CD4 + T cells remains to be determined. It has been known that IgE/ FcεRI cross-linking using multivalent Ags results in the entry of Ag/IgE/FcεRI complexes to endocytic compartments in DCs and subsequent processing and presentation of the Ags to CD4 + T cells (34, 35) . However, whether non-cross-linking Ag could follow the same pathway of DC entry has never been examined. Our finding that Fcε-linked Ag, which binds to FcεRI on DCs without crosslinking it, is presented to CD4 + T cells strongly suggests that cross-linking is not required for IgE/FcεRI entry to DC endosomal compartments. Some other work in our laboratory indicates significant amounts of IgE and FcεRI localized in endolysosomal compartments in BDCA1 + DCs freshly isolated from human blood and DCs from hFcεRIa-Tg mice (unpublished observations). Because DCs do not make IgE themselves, the presence of IgE and FcεRI in the endolysosomal compartment implies that FcεRI traffics through endocytic pathway in DCs at steady state and that IgE enters DCs by binding to FcεRI at cell surface. Ag-Fcε is likely to follow the same pathway of entry.
Ag targeting to DCs in the absence of DC maturation stimuli has been proposed to induce T cell unresponsiveness, deletion, or conversion to Tregs (9, (36) (37) (38) . Accordingly, we found that targeting Ags to FcεRI via Ag-Fcε fusion protein results in T cell deletion in hFcεRIa-Tg mice. Ag-Fcε binding to FcεRI is unlikely to activate DCs, mast cells, or basophils because it does not crosslink FcεRI. Consistently, no degranulation was observed when mast cells were incubated with Ag-Fcε. Thus, Ag presentation in these mice is likely to have been mediated by steady state immature DCs, which may then facilitate Ag-specific T cell deletion.
Indeed, when the DC maturation stimulus LPS was coinjected with OVAp-Fcε into hFcεRIa-Tg mice, OVA-specific T cells expanded and persisted over 12 d after injection, supporting the important contribution of DC activation status to T cell fate determination. Few Ag-specific Tregs were observed in our study, although others have found robust Treg induction when Ag was targeted to DEC-205 or Langerin (14, 37) . Possibly, injection of OVAp-Fcε into the peripheral tissue sites rather than blood induced Treg cells, because these cells appear to be better generated by peripheral tissue migratory DCs (14) .
DTH response is commonly examined to assess T cell-mediated immunity in vivo. A lack of DTH response to a recall Ag is regarded as an evidence of deficiency in primary T cell immunity. We found that OVAp-Fcε injection i.v. markedly inhibited hFcεRIa-Tg mice from developing OVA-specific DTH and that this inhibitory effect was completely dependent on the expression of hFcεRI in these mice. This finding strongly suggests that human FcεRI-targeted Ag is capable of undermining primary T cell immunity and developing Ag-specific tolerance in vivo. We intend to test in the near future whether injection of hFcεRIa-Tg mice with a self-antigen-or allergen-linked Fcε makes these mice resistant to autoimmune or allergic diseases.
In conclusion, this study proposes a novel approach to target Ags to human DCs for the induction of Ag-specific tolerance. Further studies on its efficacy, mechanism, and clinical safety may lead to the development of new therapeutics.
